用于治疗癌症的新型2,6,9-三取代嘌呤作为细胞周期蛋白依赖性激酶2（CDK2）抑制剂
Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers.
作者信息
Rong Jian, Liang Steven H
机构信息
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
出版信息
ACS Med Chem Lett. 2025 May 30;16(6):970-971. doi: 10.1021/acsmedchemlett.5c00282. eCollection 2025 Jun 12.
Abstract
This highlight describes novel 2,6,9-trisubstituted purines as cyclin-dependent kinase 2 (CDK2) inhibitors. It details the novel 2,6,9-trisubstituted purine compounds, the pharmaceutical composition, use, and treatment for CDK2-related diseases, such as cancers.
摘要
本综述介绍了新型2,6,9-三取代嘌呤作为细胞周期蛋白依赖性激酶2（CDK2）抑制剂的相关内容。详细阐述了新型2,6,9-三取代嘌呤化合物、药物组合物、用途以及对CDK2相关疾病（如癌症）的治疗方法。
相似文献
1
Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers.用于治疗癌症的新型2,6,9-三取代嘌呤作为细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 May 30;16(6):970-971. doi: 10.1021/acsmedchemlett.5c00282. eCollection 2025 Jun 12.
2
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
3
Licoisoflavone A inhibits colorectal cancer cell proliferation through targeting CDK2-Cyclin E1 axis-mediated cell cycle transition.甘草异黄酮A通过靶向CDK2-细胞周期蛋白E1轴介导的细胞周期转变来抑制结肠癌细胞增殖。
Biochem Pharmacol. 2025 Oct;240:117124. doi: 10.1016/j.bcp.2025.117124. Epub 2025 Jul 4.
4
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis.PI3K 和 AKT 抑制剂治疗癌症患者的疗效和安全性：系统评价和网络荟萃分析。
Eur J Pharmacol. 2024 Nov 15;983:176952. doi: 10.1016/j.ejphar.2024.176952. Epub 2024 Aug 30.
7
8
Achillea fragrantissima (Forssk.) Sch. Bip. essential oil inhibits the growth of pancreatic cancer cells via induction of necrosis, sub-G1 arrest, modulation of β-catenin/ERK signalling pathways and p38α MAPK, CDK2, EGFR inhibition.香叶蓍（Achillea fragrantissima (Forssk.) Sch. Bip.）精油通过诱导坏死、亚G1期阻滞、调节β-连环蛋白/ERK信号通路以及抑制p38α丝裂原活化蛋白激酶、细胞周期蛋白依赖性激酶2（CDK2）和表皮生长因子受体（EGFR）来抑制胰腺癌细胞的生长。
J Ethnopharmacol. 2025 Jun 24;352:120201. doi: 10.1016/j.jep.2025.120201.
9
Development of 9H-purine scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation.新型CDK2抑制剂9H-嘌呤支架的开发：设计、合成及生物学评价
Bioorg Med Chem Lett. 2025 Jul 1;122:130166. doi: 10.1016/j.bmcl.2025.130166. Epub 2025 Mar 7.
10
Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.嘌呤衍生物作为新型 CDK2 抑制剂的分子建模与设计研究。
Molecules. 2018 Nov 9;23(11):2924. doi: 10.3390/molecules23112924.
本文引用的文献
1
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.细胞周期蛋白依赖性激酶在细胞周期进程中的作用及其在人乳腺癌中的治疗策略。
Int J Mol Sci. 2020 Mar 13;21(6):1960. doi: 10.3390/ijms21061960.
2
Targeting CDK2 in cancer: challenges and opportunities for therapy.针对癌症中的 CDK2：治疗的挑战与机遇。
Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001. Epub 2019 Dec 10.
3
Interconnection between Metabolism and Cell Cycle in Cancer.癌症中代谢与细胞周期的相互联系
Trends Biochem Sci. 2019 Jun;44(6):490-501. doi: 10.1016/j.tibs.2018.12.007. Epub 2019 Jan 14.
4
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.细胞周期蛋白依赖性蛋白丝氨酸/苏氨酸激酶抑制剂作为抗癌药物。
Pharmacol Res. 2019 Jan;139:471-488. doi: 10.1016/j.phrs.2018.11.035. Epub 2018 Nov 30.
5
The history and future of targeting cyclin-dependent kinases in cancer therapy.癌症治疗中靶向细胞周期蛋白依赖性激酶的历史与未来
Nat Rev Drug Discov. 2015 Feb;14(2):130-46. doi: 10.1038/nrd4504.
Zotero 插件